Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03092011 · ClinicalTrials.gov registry record · Phase 4
Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy
A Phase 4 study of Neonatal Abstinence Syndrome, sponsored by The Cooper Health System.
- Active
- Registry status
- Phase 4
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT03092011 is a Phase 4 study of Neonatal Abstinence Syndrome that is active but no longer recruiting, run by The Cooper Health System. The registered enrollment target is 69 participants, above the 62-participant average among 17 other Neonatal Abstinence Syndrome trials with a reported enrollment target (11% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03092011, a Phase 4 study of Neonatal Abstinence Syndrome, is active but no longer recruiting, sponsored by The Cooper Health System.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to show non-inferiority between two medications used for medical treatment of withdrawal seen in Neonatal Abstinence Syndrome (NAS), Clonidine and Morphine Sulfate (used in routine care) on length of treatment for NAS .
Conditions Studied
Interventions
- DRUG Morphine Sulfate
- DRUG Clonidine
Study Locations (1)
New Jersey
- Cooper University Hospital - Camden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2018-02-21 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03092011
The ClinicalTrials.gov registry entry for NCT03092011 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 62-participant average among 17 other Neonatal Abstinence Syndrome trials with a reported enrollment target (11% higher). The listed sponsor is The Cooper Health System, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neonatal Abstinence Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Morphine Sulfate is the first listed.
NCT03092011 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT03092011 about?
NCT03092011 is a clinical study titled "Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy". The purpose of this study is to show non-inferiority between two medications used for medical treatment of withdrawal seen in Neonatal Abstinence Syndrome (NAS), Clonidine and Morphine Sulfate (used in routine care) on length of treatment for NAS .
What is the current status of trial NCT03092011?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 69 participants. The study started on 2018-02-21. Estimated completion is 2026-12-01.
What conditions does trial NCT03092011 study?
This clinical trial studies the following conditions: Neonatal Abstinence Syndrome.
What interventions are being tested in trial NCT03092011?
The interventions under investigation include: Morphine Sulfate (DRUG), Clonidine (DRUG).
Who is sponsoring clinical trial NCT03092011?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03092011 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neonatal Abstinence Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Neonatal Abstinence Syndrome
COMPLETED · Phase 4
-
Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
COMPLETED · Phase 4
-
An Intervention Mapping Approach to Closing the Gap in Maternal OUD and Infant NAS Care (SUPPORT)
RECRUITING · NA
-
MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome
RECRUITING
-
A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants
ACTIVE NOT RECRUITING · NA
-
Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.